



# mounjaro<sup>®</sup>

(tirzepatide) injection 0.5 mL

2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

## Instructions for the Epic<sup>®</sup> EHR System

Using EHR Capabilities to Support Prescribing and Continuing Treatment on Mounjaro<sup>®</sup> (tirzepatide)

EHR=electronic health record.

### INDICATION

Mounjaro (tirzepatide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

### SELECT IMPORTANT SAFETY INFORMATION

#### WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including [Boxed Warning](#) about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).

*Lilly*

A MEDICINE COMPANY

# Contents

<b>Background and Considerations</b> .....	2
<b>Utilizing EHR Prescribing Workflow Capabilities</b> .....	3
<b>Epic® Instructions</b> .....	5
How to Save Mounjaro® (tirzepatide) as a "Favorite" in Epic .....	5
Creating an OurPractice Advisory (OPA) for In Baskets .....	8
Provider Reminders (Order Instructions, Reference Link, OPA).....	11
Patient Instructions.....	17
<b>Disclaimers</b> .....	20
<b>Notes</b> .....	21
<b>Important Safety Information</b> .....	22

## Background and Considerations

One of the main goals of the EHR workflow instructions for Mounjaro® (tirzepatide) is to help support consistency in how it is prescribed. Ensuring that prescriptions are completed accurately is essential to prevent pharmacy delays or rejections. The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase to 5 mg injected subcutaneously once weekly.

Additionally, the workflow instructions will assist with how key messages are delivered to care team members and patients—including treatment-specific follow-ups and savings card resources.

The Epic® EHR system includes capabilities that may be customized to help address most of these needs by facilitating prescribing, providing patient follow-up reminders, and improving awareness of the Mounjaro Savings Card.

**This document is not intended to provide any clinical advice or recommendations, which are solely the responsibility of the health system and its healthcare providers. This information is meant to provide technical guidance and recommendations to better understand a patient population.** The process outlined in the technical instructions is variable and not all steps will apply to every health system. Any steps or settings below that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The practice is solely responsible for implementing, testing, monitoring, and maintaining the ongoing operation of any EHR tools.

These instructions are specific to adult patients with type 2 diabetes and to the Epic® EHR system and are not appropriate for other conditions, treatments, therapeutic areas, or for other EHR systems. The process outlined in this document is variable, and not all steps will apply to every health system. Steps that are not part of a standard process should be adapted accordingly. Users should contact their system administrators or appropriate service providers for questions or clarifications. The health system is responsible for selecting message content and use of patient resources, such as copay savings cards, according to their communication protocols.

# Utilizing EHR Prescribing Workflow Capabilities

## Facilitate Prescribing of Mounjaro® (tirzepatide)

### How to Save Mounjaro as a "Favorite" in Epic

New prescriptions for Mounjaro may require additional information that is not currently included in the EHR prescribing workflow.

- The prescribing details, including patient directions for taking the medication, or patient sig, for Mounjaro may include different options from other commonly prescribed type 2 diabetes medications
- Saving Mounjaro 2.5 mg/0.5 mL dose as a Favorite medication on the preference list helps ensure all prescribing details and patient instructions are accurate

## Support Patient Journey by Prompting Follow-Ups

### OurPractice Advisory (OPA)

An OPA notification may be preconfigured to automatically trigger when a new prescription for Mounjaro is signed. These messages can be sent automatically and silently to the healthcare provider's (HCP's) In Basket, or to the care team's group In Basket.

In Basket Messages function similarly to an email message inbox. An OPA that is silently delivered to an In Basket may:

- Remind HCPs to follow health system protocols for patient outreach when a new Rx is ordered
- Schedule delivery for prompt patient follow-up regarding use of the Mounjaro pen at 1 week post-prescription
- Recommend specific actions, such as increasing prescription to 5 mg/0.5 mL after 4 weeks post-prescription at 2.5 mg/0.5 mL strength

## SELECT IMPORTANT SAFETY INFORMATION

### Contraindications

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



# Utilizing EHR Prescribing Workflow Capabilities (cont.)

## Increase Awareness of the Mounjaro® (tirzepatide) Savings Card

Providing eligible and commercially insured patients with access to savings cards may support starting and staying on therapy. Health systems can update their EHR to integrate savings card information with HCP notifications when the prescription is signed. Patient-facing messages regarding the savings card can be added to patient instructions in the After Visit Summary® (AVS).

HCP-facing messages:

- Adding Order Instructions to confirm the patient's diagnosis of type 2 diabetes and confirm the patient is eligible for the copay savings card
- Adding a Reference Link to the Mounjaro Formulary Coverage and Savings Support website to the Order Screen
- Creating an OPA to notify HCPs that patients may be eligible for the Mounjaro Savings Card

Patient-facing messages:

- Adding a hyperlink to the Mounjaro Savings Card enrollment site within patient instructions in the AVS using a SmartPhrase

### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

#### Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

#### Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro. Observe patients for signs and symptoms, including persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

**Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).**



# Epic® Instructions

## How to Save Mounjaro® (tirzepatide) as a "Favorite" in Epic

Frequently written prescriptions can be saved as "Favorite" on the user's preference list in Epic®, and must be completed through the prescriber's login.

"Favorites" can be saved in the HCP's personal library or shared with all prescribers in the practice or health system.

Benefits of saving a medication as a "Favorite" include:

- Saving time when prescribing
- Ensuring accuracy and consistency



### Individual Prescriber

Individual "Favorites" appear on their personal preference list.

Individual "Favorites" are typically managed by individual prescribers.



### Practice or Facility

Shared Preferences appear on the Facility List.

Shared Facility Lists are typically managed by the information technology (IT) staff.

### Steps to Save Mounjaro as a "Favorite"

1. Search for Mounjaro in the **Database** tab.
2. Select the desired strength and formulation to display order details.

Name	Strength	Copay	Coverage	Formulary	Brand Rx
mounjaro (tirzepatide) injection 2.5 mg	2.5 mg	Retail: T3/5	Quantity Limit, Step Therapy	Preferred Level 5	Brand Rx
mounjaro (tirzepatide) injection 5 mg	5 mg	Retail: T3/5	Quantity Limit, Step Therapy	Preferred Level 5	Brand Rx
mounjaro (tirzepatide) injection 7.5 mg	7.5 mg	Retail: T3/5	Quantity Limit, Step Therapy	Preferred Level 5	Brand Rx
mounjaro (tirzepatide) injection 10 mg	10 mg	Retail: T3/5	Quantity Limit, Step Therapy	Preferred Level 5	Brand Rx
mounjaro (tirzepatide) injection 12.5 mg	12.5 mg	Retail: T3/5	Quantity Limit, Step Therapy	Preferred Level 5	Brand Rx
mounjaro (tirzepatide) injection 15 mg	15 mg	Retail: T3/5	Quantity Limit, Step Therapy	Preferred Level 5	Brand Rx

An illustrative example of the product search

### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

#### Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



# Epic® Instructions (cont.)

## How to Save Mounjaro® (tirzepatide) as a "Favorite" in Epic (cont.)

### Steps to Save Mounjaro as a "Favorite" (cont.)

3. Enter or confirm the order details such as **Dose, Route, Frequency,** and **Patient Sig.**
4. Select **Accept** to issue the prescription.

An illustrative example of the prescription details for a new Mounjaro prescription

5. Select the yellow star icon at the right of the prescription to save it as a **Favorite**.

An illustrative example of the order recap

### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

#### Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



## Epic® Instructions (cont.)

### How to Save Mounjaro® (tirzepatide) as a "Favorite" in Epic (cont.)

#### Steps to Save Mounjaro as a "Favorite" (cont.)

6. To use a "Favorite," select the prescription from the **Preference List**.

MOUNJARO 2.5 MG/0.5 mL SC SOAJ
✔ Accept
✖ Cancel

Reference Links: [Formulary Coverage and Savings](#)

Order Instructions: [Confirm patient has a type 2 diabetes diagnosis and instruct patient to visit the Mounjaro website to verify eligibility for the copay savings card.](#)

---

Product: **MOUNJARO 2.5 MG/0.5 mL SC SOAJ**

Sig Method: Specify Dose, Route, Frequency Taper/Ramp Combination Dosage

Dose:

Route:

Frequency:

Duration:  Doses Days

Starting:  Ending:  First Fill:

Dispense:  mL Refill:

Total Supply: **Unable to calculate**

Dispense As Written

Mark long-term:  TIRZEPATIDE

Patient Sig: Inject 2.5 mg subcutaneously once weekly for 4 weeks.

[+ Add additional information to the patient sig.](#)

Report: [Common sizes:](#)

Pen: 0.5 mL

Class:  Normal Print Phone In No Print Sample

Note to Pharmacy: [+ Add Note to Pharmacy \(F6\)](#)

Indications:

Type 2 Diabetes Mellitus

An illustrative example of a prescription screen with details for Mounjaro

#### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

##### Acute Kidney Injury Due to Volume Depletion

There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro. The majority of reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Mounjaro that could lead to volume depletion, especially during dosage initiation and escalation of Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).

## Epic® Instructions (cont.)

### Creating an OurPractice Advisory (OPA) for In Baskets

An OPA can be preconfigured to silently and automatically trigger when a new prescription for Mounjaro® (tirzepatide) is signed. The message can be sent to the prescriber's In Basket, similar to an email inbox, or to the care team's group In Basket. An OPA sent to an In Basket may include reminders for HCPs to follow health system protocols for patient outreach when a new Rx is ordered. In Basket Messages can also recommend a specific action, such as an HCP signing off on a new prescription for Mounjaro when the patient is scheduled to transition to a different dose.

#### Creating an OPA Rule

1. **Chart Search > Rule Editor.**
2. **Create a New Rule.**
  - Context: Patient OurPractice Advisory
  - Name: As applicable per organization standards
3. Click **Accept.**
4. Add property: Orders for Medications [34244]
  - Medications: Tirzepatide
  - Order Status: Pending
  - Search Related Encounter: No
  - Operator: Equal
  - Value: All applicable medication records
5. Click **Accept.**
6. Click **Save** (make note of new rule ID).

#### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

##### Severe Gastrointestinal Adverse Reactions

Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving Mounjaro (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Mounjaro is not recommended in patients with severe gastroparesis.

##### Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



# Epic® Instructions (cont.)

## Creating an OurPractice Advisory (OPA) for In Baskets (cont.)

### Creating a Criteria Record

1. **Chart Search > OurPractice Advisories.**
2. Click the **Create** tab.
3. Select **Record-Type** of **Criteria**.
4. Click **Accept**.
5. In the **Add Criteria Type** window, check **Rule**, then select **+Add**.
6. In the **Rule** section, add the record created in the previous steps.
7. At the top of the form, check **Release**. Then select **Save**.

### Creating an OPA Base Record

1. Chart **Search > OurPractice Advisories.**
2. From the **Create** tab, enter a name; select a **Record-Type** of **Base**.
3. In the **Display** section, enter display text such as *"New Mounjaro Rx Order"*. This OPA will be silently delivered to an In Basket, so descriptive display text will help provide context.
4. Display to user? No.
5. Select Importance level: Informational.
6. On the **Linked Criteria** form, add previously built OPA criteria records in the Linked Criteria field and set the logic as appropriate.

## SELECT IMPORTANT SAFETY INFORMATION (CONT.)

### Acute Gallbladder Disease

In placebo-controlled clinical trials in adults, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

### Pulmonary Aspiration During General Anesthesia or Deep Sedation

Mounjaro delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



# Epic® Instructions (cont.)

## Creating an OurPractice Advisory (OPA) for In Baskets (cont.)

### Setting Restrictions, Triggers, and Actions

1. **Restrictions** – This OPA will be hidden from the end user, but restrictions can be used to restrict where the OPA will be triggered.
2. **Triggers** – Set trigger(s) to determine what activity causes the OPA to display, such as Sign Order.
3. From the **Actions** section, select **+ Add Action Type**.
4. Select appropriate action type > **In Basket Message**.
  - Subject: New Mounjaro® (tirzepatide) Prescription for Follow-up
  - Message Type: For example, Management of Adverse Reactions
  - Recipients: Enter the appropriate user, class, or pool to receive In Basket message notifications to manage patient outreach
  - Appearance:
    - Message 1: "This patient has received a new Rx. Please follow Pt outreach protocol for follow-up."
    - Message 2: "This patient has completed 4 weeks of treatment. Please follow-up with new Rx for Mounjaro."
  - Frequency: Always Automatically

**Note:** Each organization will vary on which pool will receive the messages for patient outreach and the protocol for patient outreach workflow and timing. It will be up to the individual organizations how to implement timing and pools, as well as develop any associated protocol and content of messages.

The screenshot displays the Epic In Basket interface. On the left, a sidebar shows message categories: Rx Request (1/1), Patient Call (1/1), Pt Advice Request (7/7), Medication Management (11/22), Media Manager (0/1), Attached & Covering Users (1/2), Follow-up, Search, Sent Messages, and Completed Work. The main area shows a list of messages with columns for Msg Date and Subject. The selected message is dated 06/27/2025 09:17 AM with the subject 'New Mounjaro Rx for Follow-up'. The detailed view on the right shows the message content: 'New Mounjaro Rx for Follow-up' received today from 'P Clinical Support Pool'. The message body contains the text: 'This patient has received a new Rx. Please follow Pt outreach protocol for follow-up.' The interface also shows a 'PCP' field with 'Primary Cvg: Medicare/...' and a 'NEXT APPT' field.

An illustrative example on an OPA delivered to an In Basket

### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

#### Adverse Reactions in Adults

The most common adverse reactions reported in ≥5% of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



## Epic® Instructions (cont.)

### Provider Reminders (Order Instructions, Reference Link, OPA)

#### Adding Order Instructions to the Product Order Screen

When an HCP searches for and selects a medication, specific Order Instructions can be displayed to remind the HCP of important considerations, such as the need to confirm the patient's diagnosis of type 2 diabetes and check eligibility for the copay saving card.

Order Instructions are typically set up by the health system's IT support services. When making an IT request to add Order Instructions for Mounjaro® (tirzepatide), include the following information:

1. In the **Order Instructions** section, provide specific text to display; for example, use *"Confirm patient has a type 2 diabetes diagnosis and instruct patient to visit the Mounjaro website to verify eligibility for the copay savings card."*

**MOUNJARO 2.5 MG/0.5 mL SC SOAJ** ✓ Accept ✗ Cancel

Reference Links: [Formulary Coverage and Savings](#)

Order Instructions: [Confirm patient has a type 2 diabetes diagnosis and instruct patient to visit the Mounjaro website to verify eligibility for the copay savings card.](#)

Product: **MOUNJARO 2.5 MG/0.5 mL SC SOAJ**

Sig Method: **Specify Dose, Route, Frequency** | Taper/Ramp | Combination Dosage

Dose: 2.5 mg/0.5 mL

Route: Subcutaneous

Frequency: Weekly

Duration: 28 **Doses** | Days

Starting: 6/5/2025 | Ending: | First Fill: |

An illustrative example of including Order Instructions for Mounjaro

#### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

##### Drug Interactions

When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).

## Epic® Instructions (cont.)

### Provider Reminders (Order Instructions, Reference Link, OPA) (cont.)

#### Adding a Reference Link

A **Reference Link** can be added to the Order Composer to display a hyperlink to the Mounjaro Formulary Coverage and Savings Support website for HCPs.

**Reference Links** are typically set up by the health system's IT support services. When making an IT request, include the following information:

- Name and strength of the medication to which the link should be added
- Specific **Reference Links**; for example:
  - The appropriate **Display Name** for the link; for example, use [Formulary Coverage and Savings Support]
  - Any criteria under which the link should be included; for example, an initial order of the medication for the patient
- The URL which will display when the link is selected: Formulary Coverage and Savings Support | Mounjaro® (tirzepatide) [<https://mounjaro.lilly.com/hcp/savings-resources>]

#### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

##### Pregnancy

Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



## Epic® Instructions (cont.)

### Provider Reminders (Order Instructions, Reference Link, OPA) (cont.)

#### Creating an OPA

An OPA can be created to display when Mounjaro® (tirzepatide) 2.5 mg/0.5 mL is ordered. The information displayed can remind the prescriber that the patient may be eligible for the Mounjaro Savings Card, but that patient attestation is required.

Appropriate clinical or population health decision-makers should determine the final implementation of OPAs in alignment with the organization's goals and expectations. Language has been provided within technical steps for example purposes only; the organization must determine the final language used based on goals and expectations.

#### Creating an OPA Rule

1. **Chart Search > Rule Editor.**
2. **Create a New Rule.**
  - Context: Patient OurPractice Advisory
  - Name: Name according to the health system's naming conventions
3. **Select Property: Orders for Medications [34244].**
  - Medications: List desired medications to be included
    - For example, Tirzepatide, Type 2 Diabetes, (MOUNJARO) 2.5 mg/0.5 mL Subcutaneous Solution Pen Injector
  - Search Related Encounters? No
  - Order Status: Pending
  - Include/Exclude Order Status: Include

#### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

##### Lactation

In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose. There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.

##### Females of Reproductive Potential

Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

**Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).**

## Epic® Instructions (cont.)

### Provider Reminders (Order Instructions, Reference Link, OPA) (cont.)

#### Creating a Criteria Record

1. Chart **Search** > **OurPractice Advisory**.
2. **Create New Record**.
  - Name; for example, New Mounjaro® (tirzepatide) 2.5 mg/0.5 mL Rx
  - Record type: Criteria
  - Click **Continue**
  - Add **Criteria Type** of **Rule**
3. In **Rule**, add applicable **Rule** to find patients with a previously created unsigned medication order.

*An illustrative example of adding criteria to Rule section*

4. Click **Release and Save**.

#### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

##### Pediatric Use

Adverse reactions reported in pediatric patients 10 years of age and older treated with Mounjaro were similar to those reported in adults with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. The safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 10 years of age..

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



## Epic® Instructions (cont.)

### Provider Reminders (Order Instructions, Reference Link, OPA) (cont.)

#### Creating a Base Record

1. Chart **Search** > **OurPractice Advisory**.
2. **Create New Record**.
  - Name; for example, Mounjaro Copay Savings Card Reminder
  - Record type: Base
  - Click **Continue**
3. In **Display**, add applicable details for the HCP; for example:
  - Display to user? Yes
  - Unformatted Display Text: for example, Mounjaro Copay Savings Card Available
  - Formatted Display Text: For example, use "A copay savings card for Mounjaro is available for eligible, commercially insured patients. Patient attestation is required."
  - Importance Level; for example, select Important

**Note:** Importance Level may be modified based on available choices within the Importance Level dropdown menu.

4. In the **Criteria** section, add criteria created in previous steps.
5. In the **Restrictions** section, add applicable restrictions; for example, restrict by department specialty or provider type.
6. In the **Triggers** section, choose the applicable trigger, such as Sign Orders.
7. In the **Activities and Links** section, choose applicable actions to take place.

#### SELECT IMPORTANT SAFETY INFORMATION

##### WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including Boxed Warning about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



## Epic® Instructions (cont.)

### Provider Reminders (Order Instructions, Reference Link, OPA) (cont.)

#### Creating a Base Record (cont.)

**Acknowledge Reasons**

	Acknowledge Reason	Lockout	Unit	Applies To	Button	Button Caption	SmartData Element	Context	Value	Extension	Allowed Comment	Required Comment
1	Copay Savings Card Applied	Hours	All users...	No							Yes	No
2	Not Applicable	Hours	All users...	No							Yes	No
3	<input type="text"/>											

Mark all acknowledge reasons as requiring a comment

**Acknowledge Reason Settings** **Lockout When Action Taken**

Default lockout time	Unit	Acknowledge Reason Requirement	Acknowledge Reason	Lockout time	Applies to	Apply to activity links?
2	Hours	None	<input type="text"/>	Uses default lockout time	<input type="text"/>	<input type="button" value="Yes"/> <input type="button" value="No"/>

**Defer Settings** **Display Settings**

Allow deferring in mobile applications? [?](#) Acknowledge Reason Section Title

An illustrative example of including Acknowledge Reasons information

**Important (1)**

Mounjaro Copay Savings Card Available

A copay savings card for Mounjaro is available for eligible, commercially insured patients. Patient attestation is required.

Acknowledge Reason

An illustrative example of an OPA for Mounjaro® (tirzepatide)

## SELECT IMPORTANT SAFETY INFORMATION (CONT.)

### Contraindications

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including [Boxed Warning](#) about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).

# Epic® Instructions (cont.)

## Patient Instructions

### Using a SmartPhrase to Add Mounjaro® (tirzepatide) Savings Card Hyperlink to AVS

Providing eligible and commercially insured patients with access to savings cards may support starting and staying on therapy. This section provides information about using a SmartPhrase to include a link to the Mounjaro Savings Card enrollment site in the patient instructions section within an AVS report.

The health system may choose to develop and deploy SmartPhrases centrally or have clinical staff set them up; if the latter, IT department support is typically not required.

**Note:** Although this resource contains a suggested SmartPhrase title and text for illustration and convenience, the health system should independently evaluate and determine (i) which information is appropriate for capturing within a SmartPhrase and (ii) the titles and text for any SmartPhrase. Health systems should not inappropriately standardize or automate processes that require patient-by-patient consideration or judgment and should appropriately train personnel on the use and limitations of SmartPhrases before deploying them.

### Steps to Create a SmartPhrase

1. Open **SmartPhrase Editor** or as notes are documented, for example, from the Plan/Wrap-up Activity.
2. Type the desired text or phrase within the **Patient Instructions** section of a visit note. As an example, consider adding: "You may be eligible for a savings card for your Mounjaro prescription. Visit [Savings & Resources | Mounjaro® \(tirzepatide\)](#) to check eligibility and present the card to your pharmacist when you pick up your prescription. For additional support materials to your mobile device, text MJ to 85099."

### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

#### Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

#### Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro. Observe patients for signs and symptoms, including persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).




# Epic® Instructions (cont.)

## Patient Instructions (cont.)

### Steps to Create a SmartPhrase (cont.)


- Highlight the text to be included in the SmartPhrase.
- Right-click, then select **SmartPhrases > Create SmartPhrase from Selected Text**.



An illustrative example of the context menu for creating a SmartPhrase

- In the SmartPhrase Editor Settings section, enter the desired title for the SmartPhrase; for example, use ".MounjaroSavings"

**Note:** SmartPhrase titles may not contain spaces or underscores.



An illustrative example of the SmartPhrase Editor Settings section

## SELECT IMPORTANT SAFETY INFORMATION (CONT.)

### Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).

## Epic® Instructions (cont.)

### Patient Instructions (cont.)

#### Steps to Create a SmartPhrase (cont.)

- Specify desired options for formatting and logging as appropriate; add desired **Synonyms and Sharing** options.
- Click **Accept and Insert** to use in the current patient's record; to save for later use, select **Save**, then **Accept**.

An illustrative example of adding Patient Instructions using a SmartPhrase

An illustrative example of an AVS report with a hyperlink to the Mounjaro Savings Card website and enrollment form.

### SELECT IMPORTANT SAFETY INFORMATION (CONT.)

#### Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).

# Disclaimers

- The Customer (eg, the physician, medical group, integrated delivery network [IDN]) shall be solely responsible for the implementation, testing, and monitoring of the instructions to ensure proper orientation in each Customer's EHR system.
- Capabilities, functionality, and set-up (customization) for each individual EHR system may vary. Lilly shall not be responsible for revising the implementation instructions it provides to any customer in the event that the Customer modifies or changes its software, or the configuration of its EHR system, after the implementation instructions have been initially provided by Lilly.
- While Lilly tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems, and Lilly shall have no liability thereto.
- While EHRs may assist providers in identifying appropriate patients for consideration of assessment, treatment, and referral, the decision and action should ultimately be decided by a provider in consultation with the patient after a review of the patient's records to determine eligibility. Lilly shall have no liability related to a provider's decision and action (or inaction) regarding any patient identified using this resource.
- The instructions have not been designed to and are not tools and/or solutions for meeting Meaningful Use, Advancing Care Information, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)/Merit-based Incentive Payment System (MIPS) Quality Measures, and/or any other quality/accreditation requirement.
- All products are trademarks of their respective holders. All rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Lilly and/or its affiliates.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).





# Important Safety Information

## WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro.

### Contraindications

Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Mounjaro.

### Risk of Thyroid C-cell Tumors

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

### Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or Mounjaro. Observe patients for signs and symptoms, including persistent or severe abdominal pain sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue Mounjaro and initiate appropriate management.

### Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin

Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including [Boxed Warning](#) about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



# Important Safety Information (cont.)

## Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported in patients treated with Mounjaro. If hypersensitivity reactions occur, discontinue use of Mounjaro; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown if such patients will be predisposed to these reactions with Mounjaro.

## Acute Kidney Injury Due to Volume Depletion

There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or Mounjaro. The majority of reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to Mounjaro that could lead to volume depletion, especially during dosage initiation and escalation of Mounjaro.

## Severe Gastrointestinal Adverse Reactions

Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving Mounjaro (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Mounjaro is not recommended in patients with severe gastroparesis.

## Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Mounjaro has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.

## Acute Gallbladder Disease

In placebo-controlled clinical trials in adults, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

## Pulmonary Aspiration During General Anesthesia or Deep Sedation

Mounjaro delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking Mounjaro.

## Adverse Reactions in Adults

The most common adverse reactions reported in  $\geq 5\%$  of Mounjaro-treated patients in placebo-controlled trials were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

## Drug Interactions

When initiating Mounjaro, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia. Mounjaro delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

Please see additional Important Safety Information on the following pages and accompanying [Full Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#). Please see [Instructions for Use](#).



# Important Safety Information (cont.)

## Pregnancy

Limited data on Mounjaro use in pregnant women are available to inform on drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide. Use only if potential benefit justifies the potential risk to the fetus.

## Lactation

In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose. There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mounjaro and any potential adverse effects on the breastfed infant from Mounjaro or from the underlying maternal condition.

## Females of Reproductive Potential

Advise females using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

## Pediatric Use

Adverse reactions reported in pediatric patients 10 years of age and older treated with Mounjaro were similar to those reported in adults with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. The safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 10 years of age.

## Dosage Forms and Strengths:

Mounjaro is available as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL subcutaneous injection in a prefilled single-dose pen.

Please click the link to access [Prescribing Information](#), including **Boxed Warning** about possible thyroid tumors, including thyroid cancer, and [Medication Guide](#).

Please see [Instructions for Use](#) included with the pen.

TR HCP ISI 19DEC2025

The Mounjaro logo, Mounjaro®, and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. After Visit Summary® and Epic® are registered trademarks of Epic Systems Corporation.

CMAT-08593 02/2026 © Lilly USA, LLC 2026. All rights reserved.

  
**mounjaro**®  
 (tirzepatide) injection 0.5 mL  
 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg

  
 A MEDICINE COMPANY

